Drawing for EINGEFYR

USPTO serial 79301726

EINGEFYR

Reviewed by CopyMark Law Group

Reg. 6392103Status 404
Filing date
Status date
Registration date
Jun 22, 2021
Examiner
HERRERA-MARCUS, ROSELLE MORALDE
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with EINGEFYR?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthmaSECTION 70 - CANCELLED

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 8, 2025DENANOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Mar 8, 2025DETHDEATH OF INTERNATIONAL REGISTRATION
Aug 28, 2021GPNXNOTIFICATION PROCESSED BY IB
Aug 9, 2021FICSFINAL DISPOSITION NOTICE SENT TO IB
Aug 9, 2021FIMPFINAL DISPOSITION PROCESSED
Jul 22, 2021GPARGRANT OF PROTECTION CREATED, TO BE SENT TO IB
Jul 6, 2021ES7RTEAS SECTION 7 REQUEST RECEIVED
Jun 22, 2021R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 6, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 6, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 5, 2021GPNXNOTIFICATION PROCESSED BY IB
Mar 17, 2021OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 17, 2021OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Mar 17, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 4, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Feb 23, 2021DOCKASSIGNED TO EXAMINER
Feb 3, 2021CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 3, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 3, 2021ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Feb 3, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 3, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 3, 2021COARTEAS CHANGE OF OWNER ADDRESS RECEIVED
Jan 19, 2021MAFRAPPLICATION FILING RECEIPT MAILED
Jan 15, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 14, 2021LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED
Jan 7, 2021REPRSN ASSIGNED FOR SECT 66A APPL FROM IB

Frequently asked questions

Related guidance